Phase 3 trial
Annexon Advances Guillain-Barré Syndrome Awareness and Introduces Groundbreaking Targeted Therapy
Guillain-Barré Syndrome (GBS) , Annexon , Tanruprubart (ANX005) , Targeted therapy , GBS education campaign , Move GBS Forward™ , Phase 3 trial results , FDA approval
Cassava Sciences Discontinues Alzheimer’s Program After Simufilam Fails Second Phase 3 Trial
Cassava Sciences, simufilam, Alzheimer’s disease, Phase 3 trial failure, drug development discontinuation
Sanofi and Johnson & Johnson’s E. coli Vaccine Candidate Fails in Phase 3 Trial
E. coli vaccine, Sanofi, Johnson & Johnson, Phase 3 trial failure, invasive E. coli disease, ExPEC9V
Inventiva Slashes Workforce and Pipeline to Focus on MASH Drug Lanifibranor
Inventiva, layoffs, pipeline reduction, lanifibranor, MASH, Phase 3 trial, biotech restructuring
Stoke Therapeutics Announces Global Phase 3 EMPEROR Study Design for Zorevunersen in Dravet Syndrome
Dravet syndrome, zorevunersen, Phase 3 trial, EMPEROR study, seizure reduction, cognitive improvement, regulatory alignment
Tenpoint Therapeutics Prepares for 2026 Market Launch Following Successful Phase 3 Trial of BRIMOCHOL PF for Presbyopia Treatment
Tenpoint Therapeutics, BRIMOCHOL PF, Presbyopia treatment, Phase 3 trial, Combination eye drop, 2026 market launch
Pfizer’s Sasanlimab Shows Promising Results in Phase 3 Trial for High-Risk Non-Muscle Invasive Bladder Cancer
Pfizer, Sasanlimab, PD-1 Blocker, Bladder Cancer, Phase 3 Trial, Non-Muscle Invasive Bladder Cancer, BCG, Keytruda
Repare Therapeutics Advances to Phase 3 Cancer Combo Trial Following Successful MYTHIC Trial Outcomes
Repare Therapeutics, Phase 3 trial, cancer combo trial, MYTHIC trial, lunresertib, camonsertib, endometrial cancer, platinum-resistant ovarian cancer, cost-effective clinical trials
Tenpoint Therapeutics Announces Breakthrough Phase 3 Results for Presbyopia Treatment Following Merger with Visus
Tenpoint Therapeutics, Visus merger, Phase 3 trial, presbyopia treatment, BRIMOCHOL PF, vision drug, ophthalmic therapeutics
Novartis Achieves Pivotal Trial Success for Intrathecal Zolgensma in Older SMA Patients After FDA Delay
Novartis, Zolgensma, Intrathecal formulation, Spinal muscular atrophy (SMA), FDA approval, Pivotal phase 3 trial, Older SMA patients